

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X,P	WO 2015/112999 A1 (EPIC SCIENCES INC [US]) 30 July 2015 (2015-07-30) * paragraph [0039] - paragraph [0068]; claims 1-32; figures 1-4; examples 1-2 *	1-15	INV. G01N33/574 G01N33/53 C12Q1/68 G01N33/50
X	R.M. BAMBURY ET AL: "237PCHARACTERISTICS OF DE NOVO RESISTANCE TO ANDROGEN TARGETING THERAPEUTICS (AR TX) THROUGH CIRCULATING TUMOR CELLS (CTCS) ANALYSIS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS", ANNALS OF ONCOLOGY., vol. 25, no. suppl 4, 1 September 2014 (2014-09-01), pages iv79-iv79, XP55450387, NL ISSN: 0923-7534, DOI: 10.1093/annonc/mdu326.70 * abstract *	1-15	
X	H.I. SCHER ET AL: "238PCHARACTERIZATION OF CIRCULATING TUMOR CELLS (CTCS) OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS IN FIRST, SECOND & THIRD LINE SYSTEMIC THERAPIES", ANNALS OF ONCOLOGY., vol. 25, no. suppl 4, 1 September 2014 (2014-09-01), pages iv79-iv80, XP055450393, NL ISSN: 0923-7534, DOI: 10.1093/annonc/mdu326.71 * abstract *	1-15	TECHNICAL FIELDS SEARCHED (IPC) G01N
X	WO 2014/008155 A1 (GEN HOSPITAL CORP [US]) 9 January 2014 (2014-01-09) * the whole document *	1-15	
----- -/-- -----			
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search <b>The Hague</b>		Date of completion of the search <b>12 February 2018</b>	Examiner <b>Rosin, Oliver</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	

2  
EPO FORM 1503 03.82 (P04C04)

**SUPPLEMENTARY  
 EUROPEAN SEARCH REPORT**

Application Number  
 EP 15 84 4912

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (IPC)
X	US 2013/171642 A1 (PESTANO GARY [US] ET AL) 4 July 2013 (2013-07-04) * the whole document *	1-15	
X	----- Ryan Dittamore ET AL: "Molecular characterization of circulating tumor cells (CTC) and CTC subpopulations in progressive metastatic castration resistant prostate cancer (mCRPC).", Journal of Clinical Oncology, Vol 32, No 4 suppl, 1 February 2014 (2014-02-01), XP055381016, Retrieved from the Internet: URL:http://ascopubs.org/doi/abs/10.1200/jco.2014.32.4_suppl.132 [retrieved on 2017-06-13] * the whole document *	1-15	
			TECHNICAL FIELDS SEARCHED (IPC)
The supplementary search report has been based on the last set of claims valid and available at the start of the search.			
Place of search <b>The Hague</b>		Date of completion of the search <b>12 February 2018</b>	Examiner <b>Rosin, Oliver</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	

2

EPO FORM 1503 03 82 (P04C04)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 15 84 4912

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

12-02-2018

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2015112999 A1	30-07-2015	EA 201691505 A1	30-12-2016
		EP 3100046 A1	07-12-2016
		US 2016011198 A1	14-01-2016
		WO 2015112999 A1	30-07-2015
-----			
WO 2014008155 A1	09-01-2014	US 2015168413 A1	18-06-2015
		US 2017350896 A1	07-12-2017
		WO 2014008155 A1	09-01-2014
-----			
US 2013171642 A1	04-07-2013	EP 2798355 A1	05-11-2014
		US 2013171642 A1	04-07-2013
		US 2016349262 A1	01-12-2016
		WO 2013101989 A1	04-07-2013
-----			

专利名称(译)	循环肿瘤细胞诊断以鉴定对雄激素受体靶向治疗的抗性		
公开(公告)号	<a href="#">EP3198278A4</a>	公开(公告)日	2018-03-21
申请号	EP2015844912	申请日	2015-09-24
申请(专利权)人(译)	EPIC科学, INC.		
当前申请(专利权)人(译)	EPIC科学, INC.		
[标]发明人	DITAMORE RYAN		
发明人	DITAMORE, RYAN		
IPC分类号	G01N33/574 G01N33/53 C12Q1/68 G01N33/50		
CPC分类号	G01N33/57434 G01N2333/4742 G01N2333/723 G01N2800/52 G16B40/00		
优先权	62/055491 2014-09-25 US		
其他公开文献	EP3198278A1		
外部链接	<a href="#">Espacenet</a>		

摘要(译)

本公开提供了预测前列腺癌患者的肿瘤中对雄激素受体 (AR) 靶向治疗的从头抗性的方法, 其包括 (a) 进行直接分析, 所述直接分析包括免疫荧光染色和从中获得的血液样品中的有核细胞的形态特征。患者产生循环肿瘤细胞 (CTC) 数据, 其中该分析包括确定一组传统和非传统CTC生物标记物的可测量特征, 用于从头抗雄激素受体 (AR) 靶向治疗, 和 (b) 评估CTC数据以确定前列腺癌患者肿瘤中对AR靶向治疗的从头抗性的概率。进一步公开了用于该方法的传统和非传统CTC生物标记物组。

DOCUMENTS CONSIDERED TO BE RELEVANT		Relevant to:	CLASSIFICATION OF THE APPLICATION (IPC)
X, P	WO 2015/112999 A1 (EPIC SCIENCES INC [US]) 30 July 2015 (2015-07-30) * paragraph [0030] - paragraph [0068]; claims 1-32; figures 1-4; examples 1-2 *	1-15	INT. G01N33/574 G01N33/53 C12Q1/68 G01N33/50
X	R. H. BARBER ET AL.: "CHARACTERISTICS OF DE NOVO RESISTANCE TO ANDROGEN TARGING THERAPIES (AR T) THROUGH CIRCULATING TUMOR CELLS (CTCs) ANALYSIS IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS", ANNALS OF ONCOLOGY, vol. 25, no. suppl 4 1 September 2014 (2014-09-01), pages lv79-lv79, XP05545387, ISSN: 0923-7534, DOI: 10.1093/annonc/ndu326.70 * abstract *	1-15	TECHNICAL FIELD SEARCHED (IPC) G01N
X	H. I. SCHER ET AL.: "CHARACTERIZATION OF CIRCULATING TUMOR CELLS (CTCs) OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS IN FIRST, SECOND & THIRD LINE SYSTEMIC THERAPIES", ANNALS OF ONCOLOGY, vol. 25, no. suppl 4 1 September 2014 (2014-09-01), pages lv79-lv80, XP055450393, NL ISSN: 0923-7534, DOI: 10.1093/annonc/ndu326.71 * abstract *	1-15	
X	WO 2014/008155 A1 (GEN HOSPITAL CORP [US]) 9 January 2014 (2014-01-09) * the whole document *	1-15	

The EPO database search report has been filed on the last day of the month of the date of the report.

CLASSIFICATION OF THE APPLICATION (IPC):  
G01N33/574, G01N33/53, C12Q1/68, G01N33/50

TECHNICAL FIELD SEARCHED (IPC):  
G01N

SEARCHED BY: The Hague, 12 February 2018, Rosin, Oliver